South Korea
· Delayed Price · Currency is KRW Yungjin Pharm. Statistics
Total Valuation
Yungjin Pharm. has a market cap or net worth of KRW 484.67 billion.
| Market Cap | 484.67B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Yungjin Pharm. has 182.89 million shares outstanding.
| Shares Outstanding | 182.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.41% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 2.17% |
| Float | 86.95M |
Valuation Ratios
The trailing PE ratio is 49.54.
| PE Ratio | 49.54 |
| Forward PE | n/a |
| PS Ratio | 2.66 |
| PB Ratio | 4.76 |
| P/FCF Ratio | 405.99 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.06 |
| Quick Ratio | 1.20 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.94 |
| Debt / FCF | 23.50 |
| Interest Coverage | 7.93 |
Financial Efficiency
Return on equity (ROE) is 9.00% and return on invested capital (ROIC) is 5.01%.
| Return on Equity (ROE) | 9.00% |
| Return on Assets (ROA) | 3.63% |
| Return on Capital (ROIC) | 5.01% |
| Revenue Per Employee | 276.63M |
| Profits Per Employee | 14.86M |
| Employee Count | 574 |
| Asset Turnover | 0.94 |
| Inventory Turnover | 3.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.74% in the last 52 weeks. The beta is 0.86, so Yungjin Pharm.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +8.74% |
| 50-Day Moving Average | 2,442.80 |
| 200-Day Moving Average | 2,194.93 |
| Relative Strength Index (RSI) | 68.78 |
| Average Volume (20 Days) | 985,360 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Yungjin Pharm. had revenue of KRW 158.79 billion and earned 8.53 billion in profits. Earnings per share was 53.49.
| Revenue | 158.79B |
| Gross Profit | 59.28B |
| Operating Income | 9.84B |
| Pretax Income | 9.19B |
| Net Income | 8.53B |
| EBITDA | 14.48B |
| EBIT | 9.84B |
| Earnings Per Share (EPS) | 53.49 |
Balance Sheet
The company has 4.61 billion in cash and 28.06 billion in debt, giving a net cash position of -23.45 billion or -128.21 per share.
| Cash & Cash Equivalents | 4.61B |
| Total Debt | 28.06B |
| Net Cash | -23.45B |
| Net Cash Per Share | -128.21 |
| Equity (Book Value) | 99.17B |
| Book Value Per Share | 556.34 |
| Working Capital | 43.85B |
Cash Flow
In the last 12 months, operating cash flow was 6.29 billion and capital expenditures -5.09 billion, giving a free cash flow of 1.19 billion.
| Operating Cash Flow | 6.29B |
| Capital Expenditures | -5.09B |
| Free Cash Flow | 1.19B |
| FCF Per Share | 6.53 |
Margins
Gross margin is 37.34%, with operating and profit margins of 6.20% and 5.37%.
| Gross Margin | 37.34% |
| Operating Margin | 6.20% |
| Pretax Margin | 5.79% |
| Profit Margin | 5.37% |
| EBITDA Margin | 9.12% |
| EBIT Margin | 6.20% |
| FCF Margin | 0.75% |
Dividends & Yields
Yungjin Pharm. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 14.83% |
| Shareholder Yield | 14.83% |
| Earnings Yield | 2.02% |
| FCF Yield | 0.25% |
Stock Splits
The last stock split was on February 19, 2004. It was a forward split with a ratio of 2.
| Last Split Date | Feb 19, 2004 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Yungjin Pharm. has an Altman Z-Score of 3.97.
| Altman Z-Score | 3.97 |
| Piotroski F-Score | n/a |